Finance
Amgen Mulls More Green Bonds After ‘Robust Interest’ in Debut
- Pharma giant is ‘hypersensitive’ to investors, company says
- Has a sustainability target of becoming carbon neutral by 2027
This article is for subscribers only.
Pharmaceutical giant Amgen Inc. may plan to sell more bonds to benefit the environment and society after its debut green-bond got a warm reception from investors.
The maker of the blockbuster arthritis treatment Enbrel raised $4 billion in February in a four-part transaction that included a $750 million green-bond tranche, a first for Amgen. The component was six times over-subscribed by a diverse portfolio of investors, according to Judy Brown, senior vice-president of corporate affairs. That allowed the company to shave about eight basis points in borrowing costs, she added.